Last updated: July 28, 2026
Cordarone (amiodarone) remains a core antiarrhythmic in major markets. It is an established, off-patent medicine in most jurisdictions, with limited meaningful exclusivity-driven revenue upside from new clinical development. Commercial trajectory is driven by uptake in atrial fibrillation and ventricular arrhythmias, substitution patterns versus alternative antiarrhythmics (including dofetilide, sotalol, dronedarone, and catheter ablation), and safety-driven prescribing constraints.
Because “Cordarone” is a brand name and the market depends on jurisdiction, dosage form, and the specific regulatory listing (IR tablet vs IV formulation), the clinical and market picture must be aligned to the relevant product and labeling. No product-specific Orange Book or clinical-trial registry dataset was provided here, so a complete, citation-backed, drug- and jurisdiction-specific update cannot be produced.
What clinical trials update applies to Cordarone (amiodarone) in atrial fibrillation and ventricular arrhythmias?
A current “clinical trials update” for Cordarone requires tying to: (1) the exact active ingredient (amiodarone HCl), (2) the exact dosage form (oral IR vs IV), and (3) the indication and endpoints under modern trial protocols (stroke, hospitalization, mortality, AF recurrence, ventricular tachyarrhythmia suppression).
Without a linked trial dataset or registry snapshots for amiodarone/Cordarone under those exact constraints, a complete update cannot be generated.
What are the most cited modern trials for amiodarone used in AF rhythm control?
Key trial summaries in AF typically evaluate rhythm control efficacy and tolerability across antiarrhythmics and ablation strategies. A credible update requires extracting trial identifiers (NCT numbers), enrollment, design (randomized, open-label), comparator, primary endpoints, and publication dates from registries and the literature.
What trials compare amiodarone versus dronedarone, sotalol, and dofetilide?
Comparative evidence depends on era and population:
- Paroxysmal vs persistent AF
- Left ventricular dysfunction presence
- Renal impairment inclusion
- Safety endpoints (thyroid, pulmonary toxicity, bradycardia, QT effects)
A complete update needs trial-level data or citations for each comparator set.
Are there ongoing or new amiodarone trials targeting safety mitigation (e.g., dosing strategies, monitoring)
A safety-mitigation program for amiodarone usually targets:
- Lower maintenance dosing
- Structured monitoring (thyroid, liver, pulmonary)
- Drug-drug interaction reduction workflows
- Dose loading vs no-loading regimens
A real “update” requires registry extraction and milestone status.
How big is the Cordarone (amiodarone) market and where does demand concentrate?
A market analysis for Cordarone depends on:
- Geographic spend by major markets (US, EU5, Japan, China, Brazil, MENA)
- Dose-form split (oral vs IV)
- Hospital vs retail share
- Proportion of AF patients and ventricular arrhythmia cohorts that receive amiodarone at least once
- Competition effects from catheter ablation and alternative drugs
Without product- and geography-specific sales baselines (or a dataset of market shares by brand/formulation), a defensible market size and segmentation cannot be produced.
Which indications drive amiodarone use in practice?
Amiodarone demand typically clusters around:
- AF conversion and rhythm control in patients where other agents are unsuitable
- Recurrent AF after failure of other rhythm control approaches
- Ventricular tachyarrhythmia suppression where ICD is inadequate alone
A quantified analysis requires validated prescribing and claims data.
Where does amiodarone face substitution risk?
Primary substitution vectors:
- Catheter ablation for AF (reduces long-term drug dependence for some subgroups)
- Alternative antiarrhythmics with different safety profiles and monitoring burden
- In acute settings, other agents used in place of IV amiodarone in specific protocols
A projection must quantify substitution rates and persistence.
When does Cordarone exclusivity end and does it affect near-term pricing or generic erosion?
Cordarone is widely genericized across most jurisdictions. Exclusivity timing, switching dynamics, and pricing pressure depend on:
- the brand’s remaining regulatory exclusivity (if any) in a specific territory
- whether a specific dosage form or strength has unique protections
- any pediatric exclusivity or reformulation-specific exclusivity
A full exclusivity timetable requires the Orange Book status (US) and the local patent/regulatory exclusivity register status per country, plus dosage form mapping.
What is the Orange Book status of Cordarone (amiodarone) and how many ANDA pathways exist?
Orange Book analysis requires:
- listed NDA(s) for the brand name “Cordarone” and for any specific strength
- patent numbers, expiration dates, and exclusivity codes
- generic applicant entries, including Paragraph IV certifications (if any)
- litigation and settlement history tied to ANDA launches
No Orange Book listing table or patent dataset was supplied, so a complete Orange Book status page cannot be produced.
How strong is the patent estate for amiodarone/Cordarone and what generic entry risks exist?
A patent estate strength assessment needs:
- claim scope mapping (composition, formulation, method of use)
- remaining patent term by jurisdiction
- enforcement status and post-grant outcomes
- generic launch history and workarounds
Because Cordarone is an established drug, most jurisdictions rely on expired composition patents. Any remaining enforcement risk would be tied to specific dosage forms, specific methods of use, or specific formulation technologies, which must be enumerated with patent numbers and expiration dates.
What patent litigation affects Cordarone and how do settlements change launch timing?
Patent litigation requires:
- case captions, court, docket numbers, and asserted patents
- filing dates for ANDAs and Paragraph IV notices
- court rulings and settlement-triggered “carve-out” or “launch-at” dates
- FDA approval dates for first generic entries
Without litigation dockets or settlements cited to specific asserted patents, the legal impact cannot be stated.
How does Cordarone compare with dronedarone, sotalol, and dofetilide on efficacy and safety drivers?
A comparative assessment requires structured outcomes:
- rhythm control efficacy metrics (AF recurrence, conversion rates)
- hospitalization and mortality endpoints
- QT prolongation risk and torsades profiles
- extracardiac toxicity (thyroid dysfunction, pulmonary toxicity, hepatic effects)
- monitoring intensity and adherence impact
Without a referenced evidence table, any comparison would not meet the requirement for hard-data density.
What formulations are protected for Cordarone (IR vs IV) and what manufacturing/IP barriers exist?
For an IP and manufacturing barrier view, the formulation question needs:
- whether IR tablets or IV formulation is separately protected
- any protected polymorphs/solvates, excipient systems, or manufacturing processes
- device or container closure system protections (if any)
- any stability and shelf-life innovations tied to exclusivity
No formulation patent list or manufacturing data was provided.
How many clinical trials include amiodarone as an arm, and what is their status today?
Counting and status mapping requires:
- registry extraction (ClinicalTrials.gov, EU CTR, WHO ICTRP)
- indication filters (AF, ventricular tachycardia, heart failure cohorts)
- status states (recruiting, active not recruiting, completed, terminated)
- last update dates and publication links
No registry dataset was provided, so the number and status cannot be computed.
Revenue projection: What is the 5-year outlook for Cordarone (amiodarone) in US/EU and key emerging markets?
A 5-year revenue projection requires at least one of:
- a baseline sales estimate (current market size for Cordarone brand)
- a generic vs brand split model
- pricing trajectory assumptions by segment (oral vs IV)
- volume drivers (incident AF rates, aging demographics, hospital protocol changes)
- switching and persistence curves
- competitive headwinds (ablation utilization, alternative drug uptake)
No baseline sales numbers, unit volumes, or pricing assumptions were provided, so a projection would be incomplete.
What scenario framework would quantify Cordarone revenue under generic pressure?
A standard scenario framework uses:
- Brand erosion rate by year post-generic expansion
- Cross-over effects from IV use in acute care
- Net price and contracting dynamics
- Formulary coverage and prior authorization tightening
But without inputs tied to the actual market and brand share, scenario modeling cannot be produced with hard data.
Key Takeaways
- Cordarone’s near- to mid-term commercial path is driven by established use patterns, safety monitoring behavior, and substitution against ablation and other antiarrhythmics.
- A defensible, citation-backed “clinical trials update” and “revenue projection” for Cordarone requires a product- and jurisdiction-specific linkage to trial registries and regulatory listings. No such datasets were provided here, so a complete update cannot be generated under the required standards.
FAQs
- Is Cordarone still prescribed for atrial fibrillation rhythm control in the US?
- Do any new clinical trials involve low-dose or monitoring-optimized amiodarone regimens?
- How does the safety profile of amiodarone affect formulary placement versus sotalol and dofetilide?
- What impact does catheter ablation have on long-term amiodarone use rates?
- What are the main sources of generic price pressure for branded amiodarone products in major markets?
References (APA)
No sources were provided or cited.
